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Central venous obstruction is a common prob-
lem in patients with end-stage renal disease who
undergo maintenance hemodialysis.1 Interim
hemodialysis access is often achieved by inserting a
central venous catheter. Obstructions result from
frequent placement of catheters and the long dura-
tion of vein cannulation. Construction of an arterio-
venous (AV) fistula in an upper extremity with sub-
clavian vein stenosis usually results in severe venous
hypertension and arm swelling and compromises the
usefulness of the dialysis access. 
Percutaneous transluminal angioplasty (PTA),
followed by stent placement, is often effective in
dilating a stenotic segment with a significant pres-
sure gradient, and the procedure can be repeated
should obstructions recur.2 With the advent of
venous stenting, interest has swayed away from sur-
gical techniques. In general, surgery is reserved for
the occasional cases in which percutaneous proce-
dures fail or recurrent stenoses follow repeated dila-
tions/stenting. Since the introduction of venous
stents at our institution in 1994, several surgical
reports have documented that long-term patency
rates of bypass grafts3,4-7 are comparable with assist-
ed patency rates of stents,2,6,8 with equal degrees of
mortality. Therefore, we retrospectively analyzed the
long-term results of right atrial bypass grafting for
central venous obstruction associated with upper
extremity venous hypertension in nine dialysis-
dependent patients. Axillary-to–right atrial bypass
grafting in the presence of an ipsilateral AV fistula
has been successful for selected patients with symp-
tomatic subclavian vein stenosis.4
PATIENTS AND METHODS
Our analysis included nine patients (six women
and three men; average age, 59.5 years) who were
treated between June 1990 and June 1994. Clinical
Right atrial bypass grafting for central
venous obstruction associated with dialysis
access: Another treatment option
Rafik A. El-Sabrout, MD, FRCS, and J. Michael Duncan, MD, Houston, Tex
Purpose: Central venous obstruction is a common problem in patients with chronic renal
failure who undergo maintenance hemodialysis. We studied the use of right atrial bypass
grafting in nine cases of central venous obstruction associated with upper extremity
venous hypertension. To better understand the options for managing this condition, we
discuss the roles of surgery and percutaneous transluminal angioplasty with stent place-
ment. 
Methods: All patients had previously undergone placement of bilateral temporary subcla-
vian vein dialysis catheters. Severe arm swelling, graft thrombosis, or graft malfunction
developed because of central venous stenosis or obstruction in the absence of alternative
access sites. A large-diameter (10 to 16 mm) externally reinforced polytetrafluoroethyl-
ene (GoreTex) graft was used to bypass the obstructed vein and was anastomosed to the
right atrial appendage. This technique was used to bypass six lesions in the subclavian
vein, two lesions at the innominate vein/superior vena caval junction, and one lesion in
the distal axillary vein. 
Results: All patients except one had significant resolution of symptoms without operative
mortality. Bypass grafts remained patent, allowing the arteriovenous grafts to provide
functional access for 1.5 to 52 months (mean, 15.4 months) after surgery. Conclusion:
Because no mortality directly resulted from the procedure and the morbidity rate was
acceptable, this bypass grafting technique was adequate in maintaining the dialysis access
needed by these patients. Because of the magnitude of the procedure, we recommend it
only for the occasional patient in whom all other access sites are exhausted and in whom
percutaneous dilation and/or stenting has failed. (J Vasc Surg 1999;29:472-8.)
From the Department of Cardiovascular Surgery, Texas Heart
Institute at St. Luke’s Episcopal Hospital.
Reprint requests to: Dr J. Michael Duncan, MC 3-258, PO Box
20345, Houston, TX 77225. 
Copyright © 1999 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/99/$8.00 + 0 24/1/94366
JOURNAL OF VASCULAR SURGERY
Volume 29, Number 3 El-Sabrout and Duncan 473
details and patient history are summarized in Tables
I and II. Each patient had an upper extremity arterio-
venous graft (AVG) and ipsilateral central venous
obstruction caused by previously placed subclavian
catheters. Preoperative evaluation included routine
history, physical examination, laboratory tests, chest
radiograph studies, and upper extremity venograms
(bilateral in five cases) through the AVG or the basil-
ic veins. 
Patients were referred for angiography because
of recurrent AVG thrombosis, pain or swelling of the
upper extremity, or progressively increasing pressure
and decreasing blood flow during hemodialysis. In
two patients (patient 5 and patient 8), the AVG was
thrombosed and required revision at the time of
bypass grafting.
All patients had either occlusion or severe stenosis
(more than 70%) of a central venous segment (Fig 1).
The sites of obstruction (Table I) included the various
parts of the subclavian vein (six patients), the innom-
inate vein or the innominate/superior vena cava
(SVC) junction (two patients), or the axillary/subcla-
vian junction (one patient). Two patients had con-
tralateral subclavian stenosis, and two patients had
contralateral innominate vein disease.
In this group of patients, the long duration of dial-
ysis therapy (three to eight years; average, five years)
and the frequent interventions required to establish
and maintain adequate dialysis access (mean number,
12) exhausted other available access sites (Table II). All
patients had received multiple temporary bilateral 
subclavian and internal jugular vein (IJV) dialysis
catheters, and some patients had multiple failures of
contralateral upper extremity and bilateral femoral
AVGs. The use of the lower extremity for permanent
access was contraindicated in most patients (because of
severe peripheral arterial disease with limb amputation,
iliofemoral vein thrombosis with inferior vena caval fil-
ter placement, or unresolved bilateral groin infec-
tions). All patients were unsuitable candidates for or
had undergone failed attempts at peritoneal dialysis
because of multiple episodes of peritonitis, intestinal
obstruction, or bowel ischemia and colostomy. Patient
2 underwent multiple balloon dilations of an innomi-
nate/SVC stenosis and subsequently required an
innominate-to–SVC spiral saphenous vein graft
(SSVG). However, recurrent arm swelling developed
in the patient, and occlusion of the innominate
vein/SVC junction and of the SSVG were revealed by
means of an angiogram. Patient 7 underwent multiple
balloon dilations for subclavian and innominate vein
stenoses (the latter remained patent). Most patients
were not suitable candidates for transplantation
because of various comorbid conditions (Table III).
Patient 8 had undergone a renal transplantation that
subsequently failed because of noncompliance in tak-
ing medications. 
SURGICAL TECHNIQUE
The axillary-to–right-atrial bypass grafting tech-
nique (Fig 2) has been described elsewhere.9 The site
of the proximal anastomosis was determined by the
location of the obstruction. A new AVG was con-
structed in the two patients who had thrombosed
AVGs at the time of surgery. Some modifications of
the technique were dictated by individual circum-
stances. Patient 8 had a thrombosed upper arm AVG
Fig 1. Tight stenosis of the left innominate vein (arrows)
shown by means of a preoperative venogram of patient 2.
Fig 2. Schematic illustration of the bypass graft from the
axillary vein to the right atrium. The inset shows the axil-
lary and mediastinal incisions.
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and a tight midsubclavian vein stenosis. During revi-
sion of the AVG, extensive sclerosis and thrombosis of
the venous outflow to the distal axillary vein was
noted. In this case, the loop expanded polytetrafluo-
roethylene (ePTFE) AVG was anastomosed end-to-
end to a 14-mm GoreTex graft that was tunneled sub-
cutaneously and then brought through the intercostal
space and anastomosed directly to the right atrial
appendage.
RESULTS
All patients survived the operation. The postop-
erative course was uneventful in most cases, with
minimal morbidity from the median sternotomy
incision. Transient congestive heart failure devel-
oped in patient 7 because of volume overload that
resolved with adequate dialysis. A postoperative
hemothorax at the site of lysis of dense pleural adhe-
sions developed in patient 8, who was on oral anti-
coagulant therapy for a lupus erythematosus-related
hypercoagulable state. She subsequently required
open drainage and pleural decortication.
Arm edema resolved rapidly in seven patients.
Patient 1, however, had persistent arm swelling. A
tight stenosis at the subclavian vein–to-graft anasto-
mosis, which required revision with a GoreTex patch
Table I. Patient information
Patient Outcome
number Age Site of obstruction Graft Surgery Postoperative status Patency (cause of death)
1 74 Innominate/SVC 12 mm L subclavian—RA Proximal anastomosis Bypass graft failed D 2 mos with 
revision at 1 week; revised functioning
successfully; (unknown)
AVG failed at 1.5 bypass graft
months
2 62 Innominate 16 mm L axillary—RA Uneventful Bypass graft failed at D 39 months
38 mos; revised with func-
successfully; AVG tioning
patent until death bypass graft 
(tuberculosis)
3 60 Subclavian 16 mm L axillary—RA Uneventful AVG failed at 52 mos; Lost to follow-
bypass graft re- up 53 mos
mained patent with function-
ing bypass
graft
4 86 Distal subclavian 16 mm L subclavian—RA Uneventful AVG removed at 4.5 D 23 mos with
mos because of infect- functioning
ion; bypass graft bypass graft
patent until death (unknown)
5 35 Proximal subclavian 16 mm R axillary—RA Uneventful Bypass graft and AVG D 1.5 months





6 67 Midsubclavian 10 mm R axillary—RA Arm swelling as a Bypass graft and AVG D 6 mos with 
result of proximal patent until death functioning 
axillary stenosis bypass graft 
(sepsis)
7 54 Proximal subclavian 14 mm R axillary—RA Transient CHF Bypass graft and AVG D 22 mos with
patent until death functioning 
bypass graft 
(unknown)
8 27 Subclavian 14 mm L brachial artery—RA Hemothorax Bypass graft and AVG D 10 mos with
patent until death functioning 
bypass graft 
(seizures)
9 70 Distal axillary 12 mm L axillary—RA Uneventful AVG removed because Lost to follow-
of infection; bypass up 8.5 mos
graft remained patent with func-
tioning 
bypass graft
SVC, Superior vena cava; AVG, arteriovenous graft; CHF, congestive heart failure; D, died; L axillary, left axillary vein; RA, right atri-
um; R axillary, right axillary vein.
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angioplasty, was revealed by means of a venogram.
The arm swelling promptly resolved. In patient 6,
swelling persisted despite adequate flow in the
bypass graft, as documented by means of Doppler
study. The patient declined undergoing another
angiogram, but the swelling appeared to be caused
by more distal axillary venous stenosis. This AVG
remained patent until the patient died of an unrelat-
ed sepsis six months later. 
The follow-up period ranged from 1.5 to 53
months (mean, 15.5 months). Seven late deaths
occurred between 1.5 and 39 months postoperatively
because of causes completely unrelated to the proce-
dure (Table I). Two patients were lost to further fol-
low-up, one at 8.5 months and one at 53 months. All
patients were followed up clinically, and Doppler ultra-
sonography or contrast angiography was done only
when clinically indicated. At the end of the follow-up
period, six patients had relief of symptoms, and their
bypass grafts remained patent without further inter-
ventions. Two functioning AVGs were removed
because of infection, one at 4.5 months and one at six
months. Recurrent arm swelling developed in patient
2 at 38 months. A stenosis at the site where the graft
passed through the intercostal space was revealed by
means of venography, and it necessitated resection of a
portion of the second rib, segmental graft resection,
and interposition of an 8-mm ringed GoreTex graft.
The AVG and bypass graft remained patent, but the
patient died one month later of a tuberculous infection
of the cervical spine. In patient 3, the AVG failed after
52 months; extension of the occlusion to the basilic,
cephalic, and the proximal axillary veins and high-
grade stenosis of the contralateral innominate vein
were shown by means of venography.
DISCUSSION
Maintenance of functioning vascular access con-
tinues to be a serious problem for patients undergo-
ing hemodialysis. The limited number of available
sites makes the preservation of existing access
extremely important. All patients in this study had
undergone multiple upper and lower extremity
AVGs, and finding an upper extremity site for
hemodialysis graft placement was quite challenging.
Both surgical bypass graft and PTA with stent place-
ment are effective in treating central venous obstruc-
tion. Selection of the appropriate treatment in indi-
vidual patients should be based on patient life
expectancy, dialysis access longevity, and associated
comorbid factors. 
PERCUTANEOUS TRANSLUMINAL
ANGIOPLASTY WITH STENT PLACEMENT
PTA for central venous obstructions is safe and
effective,10 but restenosis lowers the long-term
patency rate. Without stent placement, the one-year
patency rates for PTA range from 12%2 to 36%,11 and
repeated interventions are often required to achieve
reasonable patency. Stents are usually indicated if the
result of balloon dilation is insufficient (leaving a
residual stenosis of at least 50% or markedly compro-
mised flow beyond the stenotic segment, with persis-
tent flow through collateral veins). Stent deployment
in treatment of de novo lesions has rapidly become the
standard treatment because central venous obstruc-
tions have a tendency to recur early and occlusions
are more difficult to treat than stenoses. They are
particularly helpful for treating highly rigid, kinked,
and collapsing stenoses, for sealing dissections or cir-
cumscribed perforations, and for establishing paten-
Table II. Patient histories
Patient number Symptoms and signs Relevant historical factors
1 Severe arm swelling Failed PD; multiple upper and lower extremity AVGs
2 Persistent arm swelling Failed PTA (3 times); status after resection and SSVG bypass grafting
3 Massive arm swelling Repair of leaking PD catheter; SBO; peritonitis; recurrent incisional hernia; 
multiple femoral Quinton catheters
4 Dialysis dysfunction Ischemic bowels; colostomy
5 AVG thrombosis Bilateral groin abscesses; left iliofemoral DVT
6 Arm swelling Severe PVD; CVA; ACB
7 Persistent arm swelling Severe PVD; bilateral AKA; SBO; extensive adhesions status after multiple PTA of 
venous stenosis
8 Hypercoagulable state (SLE), Failed PD (bleeding and infection); failed kidney transplant; 
graft thrombosis renal vein thrombosis; venous HTN LL, caused by femoral AVG; IVC filter
9 Arm swelling Failed PD and multiple upper and lower extremity AVGs
ACB, Aortocoronary bypass; AKA, above-knee amputation; AVG, atrioventricular graft; CVA, cerebrovascular accident; DVT, deep
venous thrombosis; HTN, hypertension; IVC, inferior vena cava; LL, lower limb; PD, peritoneal dialysis; PTA, percutaneous translumi-
nal angioplasty; PVD, peripheral vascular disease; SBO, small bowel obstruction; SLE, systemic lupus erythematosus; SSVG, spiral saphe-
nous vein graft. 
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cy of chronic venous occlusions.8 Stents limit elastic
vascular recoil, exclude damaged and dissected
intravascular tissue, and counteract extrinsic fibrotic
compression of the collapsed vessel.8,12 Rigid balloon-
expandable stents, such as Palmaz models (Johnson &
Johnson Interventional Systems, Warren, NJ), are poor-
ly suited to tortuous vessels and can cause intimal dam-
age and stenosis at their extremities. Collapse in the sub-
clavian position is frequently reported.13 The self-
expandable Wallstents (Schneider USA, Minneapolis,
Minn), which are designed to expand to a predeter-
mined caliber, resist compression forces in the proximal
subclavian vein. 
Surveillance and repeated interventions are
required for continued stent patency; most patients
do not attain primary patency beyond 12 months
(Table III). Documented causes of recurrence include
intrastent stenosis, stenosis immediately adjacent to
the stent, and new stenosis remote from the stent.14
Stent placement at the junction of the distal subcla-
vian and innominate veins is problematic because of dif-
fering luminal size. The deployment of a larger stent is
preferred to increase the amount of stent-to–vessel wall
contact, but ultimately it will increase pressure at the sub-
clavian vein portion, which may be a stimulus for more
rapid formation of neointimal hyperplasia and may cause
stent migration.15 An undersized stent may cause throm-
bosis. Complications directly related to stent insertion
include the development of pseudo-aneurysms, pul-
monary edema, stent infection,16 stent shortening,15 and
embolization to the pulmonary artery.14
As Vesely pointed out,15 it is difficult to make an
accurate comparison between the different stent
studies (and surgical studies) because of the many
differences in reporting methods, the mixing of
upper and lower extremity lesions, central and
peripheral lesions, Wallstents and Gianturco stents,
and 10-mm and 12-mm diameter stents. The small
number of patients in each study population also
makes statistical comparisons difficult.
SURGICAL MANAGEMENT
Since the introduction of less invasive proce-
dures, surgical repair of central venous obstructions
has been regarded as a major undertaking, limited to
low-risk patients with resistant occlusions or stent
failures. However, a recent series7 comparing the
results of stent placement with surgical bypass graft-
ing showed that stent placement is not necessarily a
superior option; the percentage of patients who were
Table III. Summary of results of percutaneous transluminal angioplasty, stent placement, and surgery for
central venous obstruction
Number of
Primary patency Assisted patency
Author Year patients 60 d 180 d 360 d 720 d 60 d 180 d 360 d 720 d
PTA procedures
Wisselink et al11 1993 15 62% 36% 0% 92% 86% 66%
Quinn et al2 1995 81% 23% 12% 100% 100% 100%
Lumsden et al22 1997 17 42% 17%
Stenting procedures
Schoenfeld et al8 1994 18 79% 68% 68% 100% 93% 93%
Criado et al6 1994 13 85% 69% 62% 85% 77% 69%
Quinn et al2 1995 19 67% 11% 11% 100% 89% 78%
Gray et al14 1995 29 46% 20% 76% 33%
Vorwerk et al23 1995 27 98% 82% 57% 45%
(90 d)
Bhatia et al7 1996 13 86% 71%
Mickley et al21 1997 14 100% 95% 70% 50% 100% 100% 100% 84%
Vesely et al15 1997 20 67% 42% 25% 88% 62% 47%
(90 d) (90 d)
Surgical procedures
Moore et al4 1991 10 (8)* 90% 89% 88% 88% 100% 100% 100% 100%)
(9/10) (8/9) (7/8) (7/8) (10/10) (9/9) (8/8) (8/8)
Gradman et al5 1994 9 (9)* 88% 75% 86% 100% 100% 100%
(7/8) (6/8) (6/7) (8/8) (8/8) (7/7)
Criado et al6 1994 4 (4)* 75% 100%
(3/4) (4/4)
Bhatia et al7 1996 13 (13)* 92% 83%
(12/13) (10/12)
El-Sabrout et al 1998 9 (9) 78% 86% 100% 100% 88% 86% 100% 100%
(7/9) (6/7) (4/4) (2/2) (7/8) (6/7) (4/4) (2/2)
*Patients with ipsilateral dialysis access.
symptom-free at six and twelve months was similar
in both groups, with no significant complications in
either group. The one-year mortality rate in both
groups was 31%. 
Several bypass grafting techniques address the
problem of central venous obstruction in the pres-
ence of an ipsilateral upper extremity dialysis access
site, with varying degrees of success (Table III). The
presence of an ipsilateral AV fistula significantly
enhances flow through the reconstructed vessel,
appears to decrease stasis and collapse, and improves
early graft patency rates (80% to 85% at one year).11
In addition, uremic patients are known to have
abnormal platelet function; this may to a certain
degree protect these patients from early graft failure. 
Choosing the appropriate method of reconstruc-
tion depends on knowing the exact location of the
lesion. Occlusions involving the innominate veins or
the SVC are bypassed with ePTFE grafts from the
axillary or the subclavian veins to the SVC or right
atrium. Lesions involving the subclavian vein at the
IJV junction are managed with IJV–to–subclavian
vein transposition (IJV turndown) or bypass graft.
In the IJV turndown technique, the ipsilateral IJV is
divided high in the neck and anastomosed to the dis-
tal subclavian vein or the axillary vein.17 Resection of
the clavicle is often required for complete mobiliza-
tion of the IJV down to the innominate vein to pre-
vent IJV kinks. This technique is a safe and efficient
method of treating isolated subclavian occlusions
that do not involve the IJV, innominate veins, or
SVC. However, this technique precludes future use
of the IJV for temporary access, hemodynamic mon-
itoring, or even venous outflow for AV fistula.18 The
resulting patency is short-lived, and reoperative
surgery of the IJV in these patients is difficult. 
Patients with occlusion of the entire subclavian
vein and a variable portion of the axillary vein can be
treated with an axillary-to-IJV bypass graft.11 Small-
diameter (6-mm) PTFE grafts have a high early-fail-
ure rate (50% in less than three months) at this site.
The use of larger (10-mm to 12-mm) grafts has
been reported with good initial results.6 In this situ-
ation, a cephalic crossover bypass graft, in which the
contralateral cephalic vein is mobilized and tunneled
to the ipsilateral shoulder to form an end-to-end
anastomosis between the two cephalic veins, can be
performed.19
Extensive thrombosis of the upper extremity
venous network is frequent in patients undergoing
dialysis after multiple central venous cannulations.1
Abundant collateral vessels often preclude precise
localization of obstructions or accurate estimation of
their length on contrast studies. Moreover, the IJVs
are not routinely visualized by means of convention-
al upper extremity venograms. The unexpected find-
ing of a diseased vein remote from the previous
entry site of the subclavian catheter, often at the
junction of the subclavian and IJV, is a frequent
occurrence. 
Subclavian vein–SVC/right atrial bypass grafting
with large PTFE grafts has also been performed with
favorable results.11,20 In addition to bypassing all
sites of obstruction, including the most central loca-
tions such as the distal subclavian vein or the innom-
inate vein/SVC junction, the technique allows the
use of larger grafts (up to 16 mm), with higher flow
rates than bypass grafts to more peripheral sites. Our
approach preserves the IJV and avoids using PTFE
in the cervical region, because PTFE infection is
common in these patients.
An externally reinforced PTFE graft resists collapse
while this graft passes through the intercostal space and
has an intraluminal surface that is relatively nonthrom-
bogenic. Selecting an appropriate length and diameter
for the graft is important in optimizing flow rates and
patency. A graft that is too small can restrict flow,
whereas a graft that is too large may be predisposed to
stasis and thrombosis because of low flow rates. 
Patency of the bypass graft does not guarantee
long-term dialysis access. In patients dependent on
dialysis, a functioning dialysis catheter is more
important than a demonstration of patency. The
high incidence of dialysis access failure resulting
from graft infection, inevitable wear and tear, or
death from other causes impedes long-term assess-
ment of any bypass grafting technique. The unfavor-
able natural history of patients undergoing dialysis
and their grafts suggests that surgical techniques
should be limited to young patients with Brescia-
Cimino fistulas or to patients with few alternate
access sites. In our patients, right atrial bypass graft-
ing was a last-ditch effort to maintain satisfactory
long-lasting dialysis access before the widespread use
of venous stents. In most instances, temporary
femoral Quinton catheters were placed after failure
of the arm AVG.
Although this technique can be modified into a
limited access operation with anterolateral thoracot-
omy, we used a median sternotomy with only mini-
mal morbidity, even in the two patients who had
undergone previous mediastinal explorations.
Although embolization from the thrombogenic graft
surface is a possibility, we did not encounter any cases
of clinically significant pulmonary embolization.
Because of associated platelet dysfunction in patients
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with end-stage renal disease, anticoagulation or
antiplatelet therapy is not required. 
Establishing a bypass graft that drains directly into
the right atrium in the presence of a patent ipsilateral
AVG can theoretically create a hyperdynamic state,
leading to high cardiac output failure. However, only
one of our patients had transient congestive heart fail-
ure in the early postoperative period; this complica-
tion was related to hypervolemia and resolved with
adequate dialysis. A similar bypass grafting technique
from the subclavian artery to the right atrium was
described elsewhere and was not associated with sig-
nificant high output cardiac failure.21
In conclusion, right atrial bypass grafting is effec-
tive in salvaging dialysis access in patients with cen-
tral venous obstruction and symptoms of upper
extremity venous hypertension. No deaths resulted
directly from the procedure, and the morbidity rate
was acceptable. With the availability of stents, how-
ever, more options to manage this condition exist.
Until further results of the efficacy and safety of
long-term use of stents are available, we recommend
that this technique be considered in patients when
other access sites have been exhausted or when per-
cutaneous dilation, stenting, or both have failed.
We thank Erin Newman in Scientific Publications at
the Texas Heart Institute for her assistance in editing this
manuscript.
REFERENCES
1. Surratt RS, Picus D, Hicks ME, Darcy MD, Kleinhoffer M,
Jendrisak M. The importance of preoperative evaluation of
the subclavian vein in dialysis access planning. AJR Am J
Roentgenol 1991;156:623-5.
2. Quinn SF, Schuman ES, Demlow TA, Standage BA, Ragsdale
JW, Green GS, et al. Percutaneous transluminal angioplasty
versus endovascular stent placement in the treatment of
venous stenoses in patients undergoing hemodialysis:
Intermediate results. J Vasc Intervent Radiol 1995;6:851-5.
3. Sottiurai VS, Lyon R, Ross C, Cooper M, Gonzales J.
Surgical management of brachioaxillary-subclavian vein
occlusion. Eur J Vasc Endovasc Surg 1996;11:225-9.
4. Moore WM Jr, Hollier LH, Pickett TK. Superior vena cava
and central venous reconstruction. Surgery 1991;110:35-41.
5. Gradman WS, Bressman P, Sernaque JD. Subclavian vein
repair in patients with an ipsilateral arteriovenous fistula. Ann
Vasc Surg 1994;8:549-56.
6. Criado E, Marston WA, Jaques PF, Mauro MA, Keagy BA.
Proximal venous outflow obstruction in patients with upper
extremity arteriovenous dialysis access. Ann Vasc Surg
1994;8:530-5.
7. Bhatia DS, Money SR, Ochsner JL, Crockett DE, Chatman
D, Dharamsey SA, et al. Comparison of surgical bypass and
percutaneous balloon dilatation with primary stent placement
in the treatment of central venous obstruction in the dialysis
patient: One-year follow-up. Ann Vasc Surg 1996;10:452-5.
8. Schoenfeld R, Hermans H, Novick A, Brener B, Cordero P,
Eisenbud D, et al. Stenting of proximal venous obstructions
to maintain hemodialysis access. J Vasc Surg 1994;19:532-9.
9. Duncan JM, Baldwin RT, Caralis JP, Cooley DA. Subclavian
vein-to-right atrial bypass for symptomatic venous hyperten-
sion. Ann Thorac Surg 1991;52:1342-3. 
10. Newman GE, Saeed M, Schwab SJ, et al. Total central vein
obstruction: Resolution with angioplasty and fibrinolysis.
Kidney Int 1991;39:761-4.
11. Wisselink W, Money SR, Becker MO, Rice KL, Ramee SR,
White CJ, et al. Comparison of operative reconstruction and
percutaneous balloon dilatation for central venous obstruc-
tion. Am J Surg 1993;66:200-5.
12. Mickley V, Gorich J, Rilinger N, Storck M, Abendroth D.
Stenting of central venous stenoses in hemodialysis patients:
long-term results. Kidney Int 1997;51:277-80.
13. Bjarmason H, Hunter D, Crain M, Ferral H, Miltz-Miller S,
Wegryn S. Collapse of a Palmaz stent in the subclavian vein.
AJR Am J Roentgenol 1993;160:1123-4.
14. Gray RJ, Horton KM, Dolmatch BL, Rundback JH, Anaise
D, Aquino AO, et al. Use of Wallstents for hemodialysis
access–related venous stenoses and occlusions untreatable
with balloon angioplasty. Radiology 1995;195:479-84.
15. Vesely TM, Hovsepian DM, Pilgram TK, Coyne DW, Shenoy
S. Upper extremity central venous obstruction in hemodialy-
sis patients: Treatment with Wallstents. Radiology 1997;204:
343-8.
16. Guest SS, Kirsch CM, Baxter R, Sorooshian M, Young J.
Infection of a venous stent in a hemodialysis patient. Am J
Kidney Dis 1995;26:377-80.
17. Puskas JD, Gertler JP. Internal jugular to axillary vein bypass
for subclavian vein thrombosis in the setting of brachial arte-
riovenous fistula. J Vasc Surg 1994;19:939-42.
18. Currier CB Jr, Widder S, Ali A, Kuusisto E, Sidawy A.
Surgical management of subclavian and axillary vein throm-
bosis in patients with a functioning arteriovenous fistula.
Surgery 1986;100:25-8.
19. Hashmonai M, Schramek A, Farbstein J. Cephalic vein cross-
over bypass for subclavian vein thrombosis: A case report.
Surgery 1976;80:563-4.
20. Piotrowski JJ, Rutherford RB. Proximal vein thrombosis sec-
ondary to hemodialysis catheterization complicated by arterio-
venous fistula. J Vasc Surg 1987;5:876-8.
21. Mickley V. Subclavian artery to right atrium haemodialysis
bridge graft for superior vena caval occlusion. Nephrol Dial
Transplant 1996;11:1361-2.
22. Lumsden AB, MacDonald MJ, Isiklar H, et al. Central
venous stenosis in the hemodialysis patient: Incidence and
efficacy of endovascular treatment. Cardiovasc Surg
1997;5:504-9.
23. Vorwerk D, Guenther RW, Mann H, Bohndorf K, Keulers P,
Alzen G, et al. Venous stenosis and occlusion in hemodialysis
shunts: Follow-up results of stent placement in 65 patients.
Radiology 1995;195:140-6.
Submitted Nov 18, 1997; accepted Aug 31, 1998.
